BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dermatrends Announces License Agreement With MINRAD International, Inc.


4/3/2007 12:31:58 PM

MINNEAPOLIS, April 3 /PRNewswire/ -- Dermatrends, Inc., a drug delivery company, announced today that it has entered into a license agreement with MINRAD International, Inc. that will allow MINRAD to use Dermatrends' patented transdermal delivery system to develop, test and deliver a new product in the conscious sedation market. The specific compound and anticipated product were not disclosed. MINRAD based in Buffalo, N.Y., is a specialty pharmaceutical and medical device company that develops, commercializes and markets products for the anesthesia, analgesic and image guidance markets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070403/CGTU006 )

Dermatrends has received an up-front license fee for its proprietary transdermal delivery technology. MINRAD and Dermatrends will work together to jointly develop the new product which would then be taken to the FDA for regulatory approval in anticipation of a market introduction. In addition to license fees, Dermatrends will receive milestone and royalty fees under terms of the agreement.

The agreement will allow MINRAD to license Dermatrends' patented hydroxide releasing agent (HRA) technology in combination with a specific active pharmaceutical ingredient (API) to produce a proprietary pharmaceutical product. Chief Executive Officer of Dermatrends, Ted Schwarzrock, said, "We are pleased to be working with an innovative leader that has been successful in multiple drug delivery systems and in several markets. MINRAD is experienced in taking products from the development stage through the regulatory process and on to commercialization and market acceptance. We are looking forward to playing an important role throughout this process as we partner with MINRAD."

About Dermatrends

Dermatrends is a privately held drug delivery and medical research company based in Minneapolis, Minn. The company is dedicated to the development of proprietary transdermal and other drug delivery technologies, and it has demonstrated an enabling platform technology that allows a broad variety of ethical and over-the-counter drugs to permeate the skin and mucosal surface and enter the bloodstream at therapeutic levels in excess of anything currently commercially available. The company is currently actively developing its partnerships and other relationships in the global pharmaceutical industry to commercially introduce its technology. Additional information is available on the company's website at http://www.dermatrends.com.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070403/CGTU006AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comDermatrends, Inc.

CONTACT: Media, Joanne Henry, +1-612-843-2142, or Products, Lee Schafer,+1-612-812-0242, both for Dermatrends, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES